SERES THERAPEUTICS INC (MCRB) Stock Analyst Ratings
USA - NASDAQ:MCRB - US81750R2013 - Common Stock
16.66 USD
-0.11 (-0.63%)
ChartMill assigns a Buy % Consensus number of 78% to MCRB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 16.32. This target is -2.04% below the current price.
MCRB was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about MCRB.
In the previous month the buy percentage consensus was at a similar level.
MCRB was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-24 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-08 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-14 | Goldman Sachs | Maintains | Sell -> Sell |
| 2024-11-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-24 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2024-09-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-06-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-06-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-01-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-11-03 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-04-28 | Chardan Capital | Maintains | Buy |
| 2023-04-21 | JP Morgan | Initiate | Neutral |
| 2023-03-21 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | Chardan Capital | Reiterate | Buy |
| 2023-03-08 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-09-07 | Piper Sandler | Maintains | Overweight |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2021-07-23 | Chardan Capital | Maintains | Buy |
| 2021-07-23 | Oppenheimer | Maintains | Outperform |
| 2021-07-23 | Canaccord Genuity | Maintains | Buy |
SERES THERAPEUTICS INC / MCRB FAQ
What is the price target for MCRB stock?
10 analysts have analysed MCRB and the average price target is 16.32 USD. This implies a price decrease of -2.04% is expected in the next year compared to the current price of 16.66.
What is the consensus rating for SERES THERAPEUTICS INC (MCRB) stock?
The consensus rating for SERES THERAPEUTICS INC (MCRB) is 78 / 100 . This indicates that analysts generally have a positive outlook on the stock.